Showing results (1-10 of 7) with videos related to
Sort By:
Pageof 1
Current Opinion in Pharmacology|September 5, 2016
GLP-1 as a target for therapeutic interventionSurya Panicker Rajeev, John WildingThe Practitioner|November 9, 2017
Set individualized targets for patients with type 2 diabetesSurya Panicker Rajeev, John WildingBMJ Case Reports|September 21, 2019
Dapagliflozin (SGLT2-i) induced euglycaemic diabetic ketoacidosisRoss Leader, Jake Cowen, Surya Panicker RajeevDiabetes Care|July 22, 2016
Positioning SGLT2 Inhibitors/Incretin-Based Therapies in the Treatment AlgorithmJohn P H Wilding, Surya Panicker Rajeev, Ralph A DeFronzoBMC Endocrine Disorders|August 25, 2014
Evolution in functionality of a metastatic pancreatic neuroendocrine tumour (pNET) causing Cushing's syndrome: treatment response with chemotherapySurya Panicker Rajeev, Steffan McDougall, Monica Terlizzo, et al.BMJ Open|January 30, 2017
Compensatory changes in energy balance during dapagliflozin treatment in type 2 diabetes mellitus: a randomised double-blind, placebo-controlled, cross-over trial (ENERGIZE)-study protocolSurya Panicker Rajeev, Victoria S Sprung, Carl Roberts, et al.Diabetes, Obesity & Metabolism|September 5, 2023
No evidence of compensatory changes in energy balance, despite reductions in body weight and liver fat, during dapagliflozin treatment in type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled, cross-over trial (ENERGIZE)Surya Panicker Rajeev, Carl Alexander Roberts, Emily Brown, et al.Pageof 1